Faron Pharmaceuticals Oy (AIM:FARN)

Market Cap	177.86M
Revenue (ttm)	n/a
Net Income (ttm)	-26.80M
Shares Out	104.62M
EPS (ttm)	-0.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,692
Average Volume	34,446
Open	167.00
Previous Close	170.00
Day's Range	167.00 - 172.00
52-Week Range	85.00 - 290.00
Beta	0.20
RSI	47.27
Earnings Date	Feb 27, 2025

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. T...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 34
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: FARN

Financial Performance

Financial numbers in EUR